During the recent session, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s traded shares were 0.68 million, with the beta value of the company hitting 1.81. At the last check today, the stock’s price was $2.19, reflecting an intraday loss of -2.88% or -$0.07. The 52-week high for the ZNTL share is $18.07, that puts it down -725.11 from that peak though still a striking 1.37% gain since the share price plummeted to a 52-week low of $2.16. The company’s market capitalization is $156.43M, and the average intraday trading volume over the past 10 days was 2.3 million shares, and the average trade volume was 1.47 million shares over the past three months.
Zentalis Pharmaceuticals Inc (ZNTL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.89. ZNTL has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.78.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Zentalis Pharmaceuticals Inc (ZNTL) registered a -2.88% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.88% in intraday trading to $2.19, hitting a weekly high. The stock’s 5-day price performance is -22.98%, and it has moved by -25.09% in 30 days. Based on these gigs, the overall price performance for the year is -84.09%. The short interest in Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is 4.54 million shares and it means that shorts have 3.92 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 78.1% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $55 respectively. As a result, ZNTL is trading at a discount of -2411.42% off the target high and -82.65% off the low.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Statistics show that Zentalis Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Zentalis Pharmaceuticals Inc (ZNTL) shares have gone down -47.86% during the last six months, with a year-to-date growth rate more than the industry average at 44.52% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -50.05%. While earnings are projected to return 45.10% in 2025.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
Zentalis Pharmaceuticals Inc insiders own 10.77% of total outstanding shares while institutional holders control 97.98%, with the float percentage being 109.81%. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the largest shareholder of the company, while 189.0 institutions own stock in it. As of 2024-06-30, the company held over 13.96 million shares (or 19.6902% of all shares), a total value of $57.1 million in shares.
The next largest institutional holding, with 8.68 million shares, is of FMR LLC’s that is approximately 12.2383% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $35.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Zentalis Pharmaceuticals Inc (ZNTL) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Mutual Fund Ser Tr-Eventide Gilead Fund. Data provided on Sep 30, 2024 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 4.95 shares. This amounts to just over 6.94 percent of the company’s overall shares, with a $10.94 million market value. The same data shows that the other fund manager holds slightly less at 3.58, or about 5.03% of the stock, which is worth about $7.92 million.
